BACKGROUND: Germline retinoblastoma (Rb) survivors are at lifelong risk for developing subsequent malignancies (SMNs). Optimal surveillance modalities are needed to detect SMN at an early stage in this high-risk cohort. We investigated the use of rapid whole-body magnetic resonance imaging (WB-MRI) as a noninvasive screening modality in this cohort. PROCEDURE: WB-MRI was performed in asymptomatic preadolescent, adolescent, or young adult survivors of germline Rb from February 1, 2008 to December 31, 2018 at a tertiary cancer center. We calculated sensitivity and specificity of WB-MRI and rate of false-positive findings requiring additional evaluation. RESULTS: Overall, 110 WB-MRI were performed in 47 germline Rb survivors (51% female; median age at initial WB-MRI: 15.5 years [range 8-25.3]). Patients received 1-10 annual WB-MRI examinations (median: two). Thirteen patients had an abnormal WB-MRI; three findings were deemed to be likely benign and were not evaluated further. Ten patients required dedicated imaging and three required biopsy; two patients were diagnosed with localized high-grade osteosarcoma, while the other eight had benign findings. One patient was diagnosed with secondary osteosarcoma 3 months after normal WB-MRI. In total, there were 96 true negatives, 11 false positives, two true positives, and one false negative. The sensitivity of WB-MRI in this cohort was 66.7% (95% confidence interval [CI], 14.2-96.0) and the specificity was 89.7% (95% CI, 83.6-93.7). CONCLUSIONS: Based on our 10-year experience, surveillance WB-MRI appears to have limited utility as a surveillance modality for SMN in germline Rb survivors. Alternate screening modalities should be investigated.
BACKGROUND: Germline retinoblastoma (Rb) survivors are at lifelong risk for developing subsequent malignancies (SMNs). Optimal surveillance modalities are needed to detect SMN at an early stage in this high-risk cohort. We investigated the use of rapid whole-body magnetic resonance imaging (WB-MRI) as a noninvasive screening modality in this cohort. PROCEDURE: WB-MRI was performed in asymptomatic preadolescent, adolescent, or young adult survivors of germline Rb from February 1, 2008 to December 31, 2018 at a tertiary cancer center. We calculated sensitivity and specificity of WB-MRI and rate of false-positive findings requiring additional evaluation. RESULTS: Overall, 110 WB-MRI were performed in 47 germline Rb survivors (51% female; median age at initial WB-MRI: 15.5 years [range 8-25.3]). Patients received 1-10 annual WB-MRI examinations (median: two). Thirteen patients had an abnormal WB-MRI; three findings were deemed to be likely benign and were not evaluated further. Ten patients required dedicated imaging and three required biopsy; two patients were diagnosed with localized high-grade osteosarcoma, while the other eight had benign findings. One patient was diagnosed with secondary osteosarcoma 3 months after normal WB-MRI. In total, there were 96 true negatives, 11 false positives, two true positives, and one false negative. The sensitivity of WB-MRI in this cohort was 66.7% (95% confidence interval [CI], 14.2-96.0) and the specificity was 89.7% (95% CI, 83.6-93.7). CONCLUSIONS: Based on our 10-year experience, surveillance WB-MRI appears to have limited utility as a surveillance modality for SMN in germline Rb survivors. Alternate screening modalities should be investigated.
Authors: Mandy L Ballinger; Ana Best; Phuong L Mai; Payal P Khincha; Jennifer T Loud; June A Peters; Maria Isabel Achatz; Rubens Chojniak; Alexandre Balieiro da Costa; Karina Miranda Santiago; Judy Garber; Allison F O'Neill; Rosalind A Eeles; D Gareth Evans; Eveline Bleiker; Gabe S Sonke; Marielle Ruijs; Claudette Loo; Joshua Schiffman; Anne Naumer; Wendy Kohlmann; Louise C Strong; Jasmina Bojadzieva; David Malkin; Surya P Rednam; Elena M Stoffel; Erika Koeppe; Jeffrey N Weitzel; Thomas P Slavin; Bita Nehoray; Mark Robson; Michael Walsh; Lorenzo Manelli; Anita Villani; David M Thomas; Sharon A Savage Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Ruth A Kleinerman; Margaret A Tucker; David H Abramson; Johanna M Seddon; Robert E Tarone; Joseph F Fraumeni Journal: J Natl Cancer Inst Date: 2007-01-03 Impact factor: 13.506
Authors: Danielle Novetsky Friedman; Eric Lis; Charles A Sklar; Kevin C Oeffinger; Marina Reppucci; Megan Harlan Fleischut; Jasmine H Francis; Brian Marr; David H Abramson; Ira J Dunkel Journal: Pediatr Blood Cancer Date: 2013-11-01 Impact factor: 3.167
Authors: Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin Journal: Lancet Oncol Date: 2011-05-19 Impact factor: 41.316
Authors: Kate A McBride; Mandy L Ballinger; Timothy E Schlub; Mary-Anne Young; Martin H N Tattersall; Judy Kirk; Ros Eeles; Emma Killick; Leslie G Walker; Sue Shanley; David M Thomas; Gillian Mitchell Journal: Fam Cancer Date: 2017-07 Impact factor: 2.375
Authors: Chu-Ling Yu; Margaret A Tucker; David H Abramson; Kyoji Furukawa; Johanna M Seddon; Marilyn Stovall; Joseph F Fraumeni; Ruth A Kleinerman Journal: J Natl Cancer Inst Date: 2009-04-07 Impact factor: 13.506
Authors: Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur Journal: Clin Cancer Res Date: 2017-07-01 Impact factor: 12.531
Authors: Sibel Saya; Emma Killick; Sarah Thomas; Natalie Taylor; Elizabeth K Bancroft; Jeanette Rothwell; Sarah Benafif; Alexander Dias; Christos Mikropoulos; Jenny Pope; Anthony Chamberlain; Ranga Gunapala; Louise Izatt; Lucy Side; Lisa Walker; Susan Tomkins; Jackie Cook; Julian Barwell; Vicki Wiles; Lauren Limb; Diana Eccles; Martin O Leach; Susan Shanley; Fiona J Gilbert; Helen Hanson; David Gallagher; Bala Rajashanker; Richard W Whitehouse; Dow-Mu Koh; S Aslam Sohaib; D Gareth Evans; Rosalind A Eeles Journal: Fam Cancer Date: 2017-07 Impact factor: 2.375
Authors: Pernille Axel Gregersen; Mikkel Funding; Jan Alsner; Maja H Olsen; Jens Overgaard; Steen F Urbak; Sandra E Staffieri; Stina Lou Journal: BMJ Open Ophthalmol Date: 2021-09-12
Authors: Haifa Al-Sarhani; Ravi V Gottumukkala; Angelo Don S Grasparil; Eric L Tung; Michael S Gee; Mary-Louise C Greer Journal: Pediatr Radiol Date: 2021-04-01
Authors: Pernille A Gregersen; Maja H Olsen; Steen F Urbak; Mikkel Funding; Susanne O Dalton; Jens Overgaard; Jan Alsner Journal: JAMA Netw Open Date: 2020-10-01
Authors: Giuseppe Petralia; Fabio Zugni; Paul E Summers; Alberto Colombo; Paola Pricolo; Luigi Grazioli; Stefano Colagrande; Andrea Giovagnoni; Anwar R Padhani Journal: Radiol Med Date: 2021-08-02 Impact factor: 3.469